All the info you could want on "Neuro-Biotech" SymPath® - Tetric™ - Axis ™ etc....
The 2000 SEC filing:
http://www.sec.gov/Archives/edgar/data/1120603/000091205700034121/0000912057-00-034121-index.htm
http://www.sec.gov/Archives/edgar/data/1120603/000091205700034121/a20fr12g.txt
The former website is still up: http://www.neuro-axis.net
hmmm...well look at that ....it looks so familar ...well it's very close to the current website don't it...
Earnest Dr. Roberge has been trying to market this stuff for over 10 years without much success.
Anyone see a SymPath® kit in their local drug store since 2000 ?
Dr. Roberge filed these interesting comments in her SEC filing:
RESEARCH AND DEVELOPMENT
The Company's research and development efforts are devoted to the development of diagnostic kits, therapeutics and clinical laboratory services. Total research and development expense for 1999 and 1998 was $1,149,885 and $1,143,741, respectively. The research and development plans for fiscal year 2000 call for
approximately $2.5 million in research and development costs. The Company plans on using SymPath-TM- revenues to fund this increase
PATENTS AND PROPRIETARY INFORMATION
There has been, and the Company believes that there may be in the future, significant litigation in the industry regarding patent and other intellectual property rights and that, if the Company becomes involved in such litigation, it could consume substantial resources. Significant legal issues remain as to the extent to which patent protection may be afforded in the field of biotechnology in the United States, Canada and other countries, and the scope of any such protection has not yet been broadly tested. The Company, therefore, also relies upon trade secrets, know-how, and continuing technological advancement to
develop and maintain its competitive position. Disclosure and use of the Company's know-how is generally controlled under agreements with the parties involved. In addition, the Company has confidentiality agreements with its key employees, consultants, officers and directors. There can be no assurance,
however, that all confidentiality agreements will be honored, that others will not independently develop equivalent technology, that disputes will not arise as to the ownership of intellectual property, or that disclosure of the Company's trade secrets will not occur. Furthermore, there can be no assurance that others
have not obtained or will not obtain patent protection that will exclude the Company from using its trade secrets and confidential information. To the extent that consultants or research collaborators use intellectual property owned by others in their work with the Company, disputes may also arise as to the rights
to related or resulting know-how or inventions.
Moreover, then Neuro-Biotech was involved in a rather nasty legal dispute involving it's shares, and one of the litigants was ...wait for it a BAHAMIAN company:
ROBERT OHAYON
Demandeur/défendeur reconventionnel
c.
ALBERT BARBUSCI
et
MORDEN C. LAZARUS
Défendeurs/demandeurs reconventionnels
et
Y. B. INVESTMENTS CORP.
Mise en cause
http://www.canlii.org/fr/qc/qccs/doc/2004/2004canlii13945/2004canlii13945.html
Recent MRES News
- M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board • InvestorsHub NewsWire • 07/19/2023 01:18:56 PM
- M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Offering Extraordinary Health and Medicinal Benefits • InvestorsHub NewsWire • 07/14/2023 12:52:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM